Agilent Technologies and Samsung Medical Centre to Collaborate on Clinical Research Projects

Agilent Technologies Inc and Samsung Medical Centre, one of South Korea’s leading medical institutes, have agreed to collaborate on medicine and genetics research projects.

The Department of Laboratory Medicine & Genetics Research, part of the Centre for Future Medicine at Samsung Medical Centre, will use Agilent’s bio-analytical instruments to analyse clinical samples and develop novel clinical assays. Clinical assays are investigative procedures that measure how drugs or biochemical substances react or respond in human samples.

“Based on our memorandum of understanding, projects such as the discovery and validation of protein biomarkers for applications in clinical trials, the development of methodology for applications involving hormones and vitamins, and assay development for a tumour marker for certain cancers and diseases will be undertaken at Samsung Medical Centre in cooperation with Agilent,” said Professor Sung-Hwa Hong, Executive Vice President, Research & Development, Samsung Medical Centre.

“For the detailed and rigorous tests required for these research projects, Agilent will provide our top-end bio-analytical instruments, on-site and remote application, and technical support, as well as our research experts to work closely with Professor Hong’s team,” said Rod Minett, General Manager of Agilent’s life sciences business in South Korea and the South Asia Pacific region. “We look forward to close collaboration with Samsung Medical Centre so as to accelerate the advancement of science and medical developments, and ultimately to improve the quality of life for mankind.”

“In addition, researchers from both Samsung Medical Centre and Agilent plan to work on join research projects that evaluate novel and powerful analytical technologies for future uses in clinical environments,” said Professor Rudolf Grimm, Agilent’s collaborations manager for South Korea and the South Asia Pacific region.